Argenx Se ARGX.BR

Founded in 2008, Argenx SE is a Dutch pharmaceutical company specialising in the research and development of cures for cancer and autoimmune diseases. The company focuses on medicinal solutions in areas where little progress has been made historically. Argenx uses a proprietary technology called SIMPLE Antibody Platform, allowing the company to find answers for complex medical questions. In tandem with its platform technology, Argenx employs several different bioengineering methods.

Traded as ARGX, Argenx is a dual-listed stock, available for trade on the Nasdaq and Euronext exchanges. The company first went public on the Euronext, with a 2014 IPO that gave the company a market valuation of €131.7 million. Argenx was listed on the Nasdaq in 2017, raising almost $100 million with $17 per share.

Argenx often partners with other leading pharmaceutical companies to solve complex medical problems. Some of these partners include LEO Pharma, a skincare provider, Shire, a healthcare company that provides patients with life-saving medical solutions, and Staten Technology, a biotechnology company aiming to remedy cardiovascular ailments.

Diversify and trade. Start now with ARGX stock.